Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
N
Shared by NobleBlocks on Nov 1, 2022 • 12:00 AM UTC
Authors:
F. Griesinger
,
G. Curigliano
,
M. Thomas
Research Assistant
AI chat, annotations, notes & similar papers
Finding related papers...
Discussions
(0)
No comments yet
Be the first to share your thoughts!
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial | NobleBlocks
